Avid Radiopharmaceuticals' Imaging Agent to be Licensed by Bayer Schering Pharma
|
By MedImaging staff writers Posted on 05 Jul 2007 |
|
Avid Radiopharmaceuticals, Inc. (Philadelphia, PA, USA), a product-focused molecular imaging company, and Bayer Schering Pharma (Berlin, Germany), a world leader in the diagnostic imaging pharmaceutical field, announced that Bayer Schering Pharma has exercised its right to license Avid's 18F-AV1/ZK compound, a molecular imaging agent that targets amyloid plaques in the brain.
When used with positron emission tomography (PET) imaging, the AV1/ZK compound may enable earlier and more accurate diagnosis of Alzheimer's disease (AD), a disease that currently affects an estimated five million individuals in the United States alone and is expected to potentially affect up to 16 million Americans by the year 2050.
"We are very pleased that Bayer Schering is committed to the field of molecular imaging and to the development of AV1/ZK,” said Daniel Skovronsky, M.D., Ph.D., president and CEO of Avid. "This is an endorsement of both the potential clinical value of AV1/ZK as well as our product pipeline of molecular imaging compounds for early diagnosis of AD, Parkinson's disease [PD] and dementia with Lewy Bodies [DLB]. To have a world-class company like Bayer Schering invest in this field will only accelerate the development of new products like AV1/ZK to the benefit of both physicians and AD patients in the future.”
AV1/ZK is one of a series of novel compounds discovered in the laboratory of Dr. Hank Kung, from the University of Pennsylvania (Philadelphia, PA, USA), and exclusively licensed to Avid for development and commercialization. Avid entered into an exclusive option agreement with Schering AG (now Bayer Schering Pharma) in December 2005 for the development of AV1/ZK and related compounds referred to as 18F-stilbenes for positron emission tomography (PET) imaging of Alzheimer's disease.
New treatment methods for slowing or reversing the deposition of insoluble amyloid in the brains of individuals with Alzheimer's disease are the subject of intensive clinical research by many large pharmaceutical companies as well as the U.S. National Institute of Mental Health (NIMH; Bethesda, MD, USA). It is anticipated that molecular imaging agents such as those being developed by Avid may help in identifying Alzheimer's patients who will benefit from these emerging treatments.
Related Links:
Avid Radiopharmaceuticals
Bayer Schering Pharma
NIMH
When used with positron emission tomography (PET) imaging, the AV1/ZK compound may enable earlier and more accurate diagnosis of Alzheimer's disease (AD), a disease that currently affects an estimated five million individuals in the United States alone and is expected to potentially affect up to 16 million Americans by the year 2050.
"We are very pleased that Bayer Schering is committed to the field of molecular imaging and to the development of AV1/ZK,” said Daniel Skovronsky, M.D., Ph.D., president and CEO of Avid. "This is an endorsement of both the potential clinical value of AV1/ZK as well as our product pipeline of molecular imaging compounds for early diagnosis of AD, Parkinson's disease [PD] and dementia with Lewy Bodies [DLB]. To have a world-class company like Bayer Schering invest in this field will only accelerate the development of new products like AV1/ZK to the benefit of both physicians and AD patients in the future.”
AV1/ZK is one of a series of novel compounds discovered in the laboratory of Dr. Hank Kung, from the University of Pennsylvania (Philadelphia, PA, USA), and exclusively licensed to Avid for development and commercialization. Avid entered into an exclusive option agreement with Schering AG (now Bayer Schering Pharma) in December 2005 for the development of AV1/ZK and related compounds referred to as 18F-stilbenes for positron emission tomography (PET) imaging of Alzheimer's disease.
New treatment methods for slowing or reversing the deposition of insoluble amyloid in the brains of individuals with Alzheimer's disease are the subject of intensive clinical research by many large pharmaceutical companies as well as the U.S. National Institute of Mental Health (NIMH; Bethesda, MD, USA). It is anticipated that molecular imaging agents such as those being developed by Avid may help in identifying Alzheimer's patients who will benefit from these emerging treatments.
Related Links:
Avid Radiopharmaceuticals
Bayer Schering Pharma
NIMH
Radiology Software
DxWorks
New
Post-Processing Imaging System
DynaCAD Prostate
New
Breast Localization System
MAMMOREP LOOP
Digital X-Ray Detector Panel
Acuity G4
Latest Industry News News
- GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
- Patient-Specific 3D-Printed Phantoms Transform CT Imaging
- Siemens and Sectra Collaborate on Enhancing Radiology Workflows
- Bracco Diagnostics and ColoWatch Partner to Expand Availability CRC Screening Tests Using Virtual Colonoscopy
- Mindray Partners with TeleRay to Streamline Ultrasound Delivery
- Philips and Medtronic Partner on Stroke Care
- Siemens and Medtronic Enter into Global Partnership for Advancing Spine Care Imaging Technologies
- RSNA 2024 Technical Exhibits to Showcase Latest Advances in Radiology
- Bracco Collaborates with Arrayus on Microbubble-Assisted Focused Ultrasound Therapy for Pancreatic Cancer
- Innovative Collaboration to Enhance Ischemic Stroke Detection and Elevate Standards in Diagnostic Imaging
- RSNA 2024 Registration Opens
- Microsoft collaborates with Leading Academic Medical Systems to Advance AI in Medical Imaging
- GE HealthCare Acquires Intelligent Ultrasound Group’s Clinical Artificial Intelligence Business
- Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions
- Polish Med-Tech Company BrainScan to Expand Extensively into Foreign Markets
- Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
Channels
Radiography
view channel
Machine Learning Algorithm Identifies Cardiovascular Risk from Routine Bone Density Scans
A new study published in the Journal of Bone and Mineral Research reveals that an automated machine learning program can predict the risk of cardiovascular events and falls or fractures by analyzing bone... Read more
AI Improves Early Detection of Interval Breast Cancers
Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more
World's Largest Class Single Crystal Diamond Radiation Detector Opens New Possibilities for Diagnostic Imaging
Diamonds possess ideal physical properties for radiation detection, such as exceptional thermal and chemical stability along with a quick response time. Made of carbon with an atomic number of six, diamonds... Read more
MRI
view channel
Simple Brain Scan Diagnoses Parkinson's Disease Years Before It Becomes Untreatable
Parkinson's disease (PD) remains a challenging condition to treat, with no known cure. Though therapies have improved over time, and ongoing research focuses on methods to slow or alter the disease’s progression,... Read more
Cutting-Edge MRI Technology to Revolutionize Diagnosis of Common Heart Problem
Aortic stenosis is a common and potentially life-threatening heart condition. It occurs when the aortic valve, which regulates blood flow from the heart to the rest of the body, becomes stiff and narrow.... Read more
Ultrasound
view channel
New Incision-Free Technique Halts Growth of Debilitating Brain Lesions
Cerebral cavernous malformations (CCMs), also known as cavernomas, are abnormal clusters of blood vessels that can grow in the brain, spinal cord, or other parts of the body. While most cases remain asymptomatic,... Read more.jpeg "Image: The AI-powered lung ultrasound tool outperformed human experts by 9% in diagnosing TB (Photo courtesy of Adobe Stock)")
AI-Powered Lung Ultrasound Outperforms Human Experts in Tuberculosis Diagnosis
Despite global declines in tuberculosis (TB) rates in previous years, the incidence of TB rose by 4.6% from 2020 to 2023. Early screening and rapid diagnosis are essential elements of the World Health... Read more
Nuclear Medicine
view channel
New Imaging Approach Could Reduce Need for Biopsies to Monitor Prostate Cancer
Prostate cancer is the second leading cause of cancer-related death among men in the United States. However, the majority of older men diagnosed with prostate cancer have slow-growing, low-risk forms of... Read more
Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors
Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more
General/Advanced Imaging
view channel
First-Of-Its-Kind Wearable Device Offers Revolutionary Alternative to CT Scans
Currently, patients with conditions such as heart failure, pneumonia, or respiratory distress often require multiple imaging procedures that are intermittent, disruptive, and involve high levels of radiation.... Read more
AI-Based CT Scan Analysis Predicts Early-Stage Kidney Damage Due to Cancer Treatments
Radioligand therapy, a form of targeted nuclear medicine, has recently gained attention for its potential in treating specific types of tumors. However, one of the potential side effects of this therapy... Read more
Imaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
